GlassScriptPhysician profile
Victoria Nytch
NPI 1689123853
$4,937.61
in general payments reported to CMS, 2019-2025
19 companies · $511 in 2025
The $511 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.00 · 2022: $3,716 · 2023: $232 · 2024: $381 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,123.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $2,890.40 | 2022 | |
| Novus Surgical Solutions LLC | $825.87 | 2022 | |
| Acumed LLC | $205.37 | 2024 | Acumed, Innate Implant |
| Stryker Corporation | $194.26 | 2023-2025 | Molli, Triathlon, Spy-Phi System |
| Smith+Nephew, INC. | $164.19 | 2025 | Renasys Go V2 Home |
| Medacta USA, INC. | $133.24 | 2023 | Gmk Sphere |
| Medical Device Business Services, INC. | $98.00 | 2021 | |
| Becton, Dickinson and Company | $89.65 | 2025 | Surgiphor |
| Stemline Therapeutics INC. | $68.20 | 2024-2025 | Orserdu |
| Daiichi Sankyo INC. | $54.00 | 2024-2025 | Enhertu |
| Recordati_rare_diseases_inc. | $41.33 | 2024-2025 | Sylvant |
| Si-Bone, INC. | $33.49 | 2024 | |
| Sun Pharmaceutical Industries INC. | $26.52 | 2024 | |
| Apellis Pharmaceuticals, INC. | $24.88 | 2024 | Empaveli |
| Merck Sharp & Dohme LLC | $23.02 | 2025 | Lynparza, Keytruda |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $18.96 | 2025 | Zoladex |
| Aveo Pharmaceuticals, INC. | $17.86 | 2025 | |
| Emd Serono, INC. | $14.72 | 2024 | |
| Genmab U.S., INC. | $13.65 | 2025 | Tivdak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Nytch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.